πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9278110

Anti-regurgitation and/or anti-gastrooesophageal reflux composition, preparation and uses

UNITED PHARMACEUTICALS Β· Granted Tue Mar 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9273143

Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EG

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9272137

Transdermal methods and systems for the delivery of anti-migraine compounds

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9273136

Fully human anti-human NKG2D monoclonal antibodies

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9265827

Anti-PDGFR-beta antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9266960

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of sa

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9259488

Anti-C3d antibody conjugates and methods of detecting complement activation

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Feb 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9249225

Single chain variable fragment anti-CD133 antibodies and uses thereof

Regents of the University of Minnesota Β· Granted Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9243036

Anti-microbial activity of synthetic peptides

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9238692

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9233932

Oligomer-nitroimidazole anti-infective conjugates

Nektar Therapeutics Β· Granted Tue Jan 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9220772

Anti-tumor antigen antibodies and methods of use

The Regents of the University of California Β· Granted Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9216983

Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity

The Board of Regents of the University of Texas System Β· Granted Tue Dec 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9211244

Method for anti-skin aging using caffeamide derivative

China Medical University Β· Granted Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9200265

Anti-cocaine compositions and treatment

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9193801

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9187541

Anti-microbial peptides and methods of use thereof

The Regents of the University of California Β· Granted Tue Nov 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9181327

Anti-HIV domain antibodies and method of making and using same

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9173880

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9168291

Ξ²-mannosylceramide and stimulation of NKT cell anti-tumor immunity

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9169294

Anti-angiogenic molecules, nanostructures and uses thereof

Northwestern University Β· Granted Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9168269

Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9161935

Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF the

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9163085

Anti-OX40 antibodies and methods of treating cancer

The Board of Regents of the University of Texas System Β· Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted